

AI-Driven Diabetic Retinopathy Screening Market - 2024-2033

<https://marketpublishers.com/r/A0D4A8876672EN.html>

Date: February 2026

Pages: 186

Price: US\$ 2,999.00 (Single User License)

ID: A0D4A8876672EN

Abstracts

The AI-Driven Diabetic Retinopathy Screening Market was valued at US\$ 0.4 Billion in 2024 and is anticipated to reach US\$ 2.22 Billion by 2033, at a CAGR of 0.21 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the AI-Driven Diabetic Retinopathy Screening Market.

This report delivers a comprehensive overview of the AI-Driven Diabetic Retinopathy Screening Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AI-Driven Diabetic Retinopathy Screening Market. The AI-Driven Diabetic Retinopathy Screening Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

AI-Driven Diabetic Retinopathy Screening Market Scope:

By Component

Software

Hardware

Services

By Screening Modality

Automated Screening

Semi-Automated Screening

Tele-ophthalmology-Integrated Screening

By Disease Severity Classification

No Apparent Diabetic Retinopathy

Mild Non-Proliferative Diabetic Retinopathy (NPDR)

Moderate Non-Proliferative Diabetic Retinopathy (NPDR)

Severe Non-Proliferative Diabetic Retinopathy (NPDR)

Proliferative Diabetic Retinopathy (PDR)

Diabetic Macular Edema (DME) Detection

By Imaging Technology

Fundus Photography

Optical Coherence Tomography (OCT)

Ultra-Widefield Retinal Imaging

Fluorescein Angiography (AI-assisted analysis)

Multimodal Retinal Imaging (Fundus + OCT + Clinical Data)

By End User

Hospitals

Clinics

Ambulatory Surgical Centers (ASCs)

Primary Care Settings

Others

By Deployment Mode

On-Premises

Cloud-Based

Hybrid Deployment

By Clinical Workflow Integration

Standalone AI Screening Tools

By AI Technology

Deep Learning (CNN-based models)

Machine Learning (Traditional classifiers)

Computer Vision Algorithms

Ensemble AI Models

Explainable AI (XAI) Systems

By Application

Mass Population Screening

Early Disease Detection & Risk Assessment

Disease Progression Monitoring

Treatment Response Monitoring

Referral Decision Support

Clinical Research & Real-World Evidence Generation

By Patient Demographics

Adult Diabetic Population

Pediatric & Adolescent Diabetics

Geriatric Population

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes (screening use cases)

By Regulatory & Validation Status

Research-Use-Only (RUO) Systems

Clinically Validated AI Tools

Regulatory-Approved Systems (FDA, CE, CDSCO)

Reimbursement-Eligible AI Solutions

Key Players

Digital Diagnostics Inc.

Topcon Healthcare

Eyenuk, Inc.

AEYE Health

IRIS (Intelligent Retinal Imaging Systems).

Optomed Plc

Forus Health (3nethra)

iCare

Major Highlights

This report delivers a comprehensive overview of the AI-Driven Diabetic Retinopathy Screening Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding AI-Driven Diabetic Retinopathy Screening Market. The AI-Driven Diabetic Retinopathy Screening Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for

the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client,

gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Diabetes & Diabetic Retinopathy
 - 3.1.1.2. Advancements in AI Technology
 - 3.1.1.3. Focus on Accessibility & Point-of-Care Screening
 - 3.1.2. Restraints
 - 3.1.2.1. High Initial Implementation Costs
 - 3.1.2.2. Data Privacy and Cybersecurity Concerns
 - 3.1.3. Opportunity
 - 3.1.3.1. Cloud-Based & Scalable Software Solutions
 - 3.1.3.2. Partnerships & Public-Private Initiatives
 - 3.1.4. Trends
 - 3.1.4.1. Rise of Portable & Edge-Computing AI Devices
 - 3.1.4.2. High Diagnostic Accuracy & Performance Gains
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global AI-Driven Diabetic Retinopathy Screening Market

4.2. Geopolitical & Supply Chain Exposure

- 4.2.1. Concentration of annotated retinal image datasets
- 4.2.2. Dependence on region-specific clinical validation data

4.3. Social & Patient-Centric Factors

- 4.3.1. Physician Acceptance & Trust in AI-Assisted DR Diagnosis
- 4.3.2. Human Grader Preference vs Algorithm-Based Screening
- 4.3.3. Patient Compliance & Screening Uptake in Asymptomatic Diabetes
- 4.3.4. Awareness Gaps in AI-Enabled Preventive Eye Care

4.4. Economic Factors

- 4.4.1. Public Health Screening Budgets & Reimbursement Structures
- 4.4.2. Cost Pressure on AI Development, Validation & Deployment
- 4.4.3. Currency & Localization Costs Impacting Global AI Vendors

4.5. Pricing Analysis

- 4.5.1. AI Screening Pricing Models

4.6. Regulatory Analysis

- 4.6.1. Regulatory Approval Pathways for AI-Based DR Screening
- 4.6.2. Post-Market Surveillance & Algorithm Performance Monitoring
- 4.6.3. Quality Management, Cybersecurity & Compliance Risks
- 4.6.4. Regional Regulatory Alignment & Fragmentation

4.7. Go-To-Market (GTM) Strategy

- 4.7.1. Deployment Across Healthcare Settings

4.8. Innovation & R&D Trends

- 4.8.1. Algorithm Enhancement & Multi-Disease Retinal Screening
- 4.8.2. Integration with Imaging Hardware & EHR Systems

4.9. Sustainability and ESG Analysis

- 4.9.1. Ethical AI, Data Governance & Healthcare Equity

4.10. AI-Driven DR Screening Ecosystem Participants

- 4.10.1. AI Software & Algorithm Developers
- 4.10.2. Retinal Imaging Device Manufacturers
- 4.10.3. Cloud Infrastructure & AI Platform Providers
- 4.10.4. System Integrators & Telehealth Providers
- 4.10.5. Public Health Agencies, NGOs & Screening Program Operators

4.11. Buyer Decision Criteria & Adoption Drivers

- 4.11.1. Diagnostic Accuracy & Clinical Validation
- 4.11.2. Regulatory Clearance & Compliance Track Record

- 4.11.3. Scalability, Deployment Speed & Workflow Integration
- 4.11.4. Cost-Effectiveness & Population-Level Screening Impact
- 4.12. DMI Opinion – Strategic Outlook for the Global AI-Driven Diabetic Retinopathy Screening Market

5. BY COMPONENT

5.1. Introduction

- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 5.1.2. Market Attractiveness Index, By Component

5.2. Software

- 5.2.1. Image analysis & deep learning algorithms
- 5.2.2. Clinical decision support systems (CDSS)
- 5.2.3. Risk stratification & progression prediction software
- 5.2.4. Workflow integration & PACS connectivity
- 5.2.5. Data management & interoperability platforms

5.3. Hardware

- 5.3.1. Fundus cameras (non-mydrionic / mydrionic)
- 5.3.2. Portable & handheld retinal imaging devices
- 5.3.3. Smartphone-based retinal imaging systems
- 5.3.4. Edge AI processing units
- 5.3.5. AI-enabled OCT systems

5.4. Services

- 5.4.1. AI model training & validation services
- 5.4.2. Deployment, integration & customization services
- 5.4.3. Cloud hosting & data storage services
- 5.4.4. Regulatory compliance & clinical validation services
- 5.4.5. Post-deployment monitoring & technical support

6. BY SCREENING MODALITY

6.1. Introduction

- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
- 6.1.2. Market Attractiveness Index, By Screening Modality

6.2. Automated Screening

- 6.2.1. Fully autonomous AI diagnostic systems
- 6.2.2. FDA/CE-approved autonomous detection tools
- 6.2.3. Population-scale screening platforms

6.3. Semi-Automated Screening

- 6.3.1. AI-assisted clinician review systems
- 6.3.2. Human-in-the-loop diagnostic platforms
- 6.3.3. AI-triage tools for referral prioritization
- 6.4. Tele-ophthalmology-Integrated Screening
 - 6.4.1. Remote AI-based DR screening
 - 6.4.2. Community-based mobile screening programs
 - 6.4.3. Rural & underserved population screening

7. BY DISEASE SEVERITY CLASSIFICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
 - 7.1.2. Market Attractiveness Index, By Disease Severity Classification
- 7.2. No Apparent Diabetic Retinopathy
- 7.3. Mild Non-Proliferative Diabetic Retinopathy (NPDR)
- 7.4. Moderate Non-Proliferative Diabetic Retinopathy (NPDR)
- 7.5. Severe Non-Proliferative Diabetic Retinopathy (NPDR)
- 7.6. Proliferative Diabetic Retinopathy (PDR)
- 7.7. Diabetic Macular Edema (DME) Detection

8. BY IMAGING TECHNOLOGY

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
 - 8.1.2. Market Attractiveness Index, By Imaging Technology
- 8.2. Fundus Photography
- 8.3. Optical Coherence Tomography (OCT)
- 8.4. Ultra-Widefield Retinal Imaging
- 8.5. Fluorescein Angiography (AI-assisted analysis)
- 8.6. Multimodal Retinal Imaging (Fundus + OCT + Clinical Data)

9. BY END USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 9.1.2. Market Attractiveness Index, By End User
- 9.2. Hospitals
 - 9.2.1. Tertiary care hospitals

- 9.2.2. Teaching & academic hospitals
- 9.3. Clinics
 - 9.3.1. Ophthalmology clinics
 - 9.3.2. Chain diagnostic laboratories
- 9.4. Ambulatory Surgical Centers (ASCs)
- 9.5. Primary Care Settings
 - 9.5.1. General practitioner clinics
 - 9.5.2. Community health centers
- 9.6. Others
 - 9.6.1. Pharmacies with point-of-care screening
 - 9.6.2. Mobile screening units
 - 9.6.3. Government & public health programs

10. BY DEPLOYMENT MODE

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
 - 10.1.2. Market Attractiveness Index, By Deployment Mode
- 10.2. On-Premises
 - 10.2.1. Hospital-based AI servers
 - 10.2.2. Edge-based AI inference systems
- 10.3. Cloud-Based
 - 10.3.1. SaaS AI diagnostic platforms
 - 10.3.2. Hybrid cloud clinical systems
- 10.4. Hybrid Deployment
 - 10.4.1. Edge + cloud inference architecture
 - 10.4.2. Offline-first AI screening solutions

11. BY CLINICAL WORKFLOW INTEGRATION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
 - 11.1.2. Market Attractiveness Index, By Clinical Workflow Integration
- 11.2. Standalone AI Screening Tools
 - 11.2.1. EHR-Integrated AI Systems
 - 11.2.2. PACS-Integrated AI Platforms
 - 11.2.3. Referral & Care Pathway Automation Systems

12. BY AI TECHNOLOGY

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology

12.1.2. Market Attractiveness Index, By AI Technology

12.2. Deep Learning (CNN-based models)

12.3. Machine Learning (Traditional classifiers)

12.4. Computer Vision Algorithms

12.5. Ensemble AI Models

12.6. Explainable AI (XAI) Systems

13. BY APPLICATION

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

13.1.2. Market Attractiveness Index, By Application

13.2. Mass Population Screening

13.3. Early Disease Detection & Risk Assessment

13.4. Disease Progression Monitoring

13.5. Treatment Response Monitoring

13.6. Referral Decision Support

13.7. Clinical Research & Real-World Evidence Generation

14. BY PATIENT DEMOGRAPHICS

14.1. Introduction

14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics

14.1.2. Market Attractiveness Index, By Patient Demographics

14.2. Adult Diabetic Population

14.3. Pediatric & Adolescent Diabetics

14.4. Geriatric Population

14.5. Type 1 Diabetes

14.6. Type 2 Diabetes

14.7. Gestational Diabetes (screening use cases)

15. BY REGULATORY & VALIDATION STATUS

15.1. Introduction

- 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 15.1.2. Market Attractiveness Index, By Region
- 15.2. Research-Use-Only (RUO) Systems
- 15.3. Clinically Validated AI Tools
- 15.4. Regulatory-Approved Systems (FDA, CE, CDSCO)
- 15.5. Reimbursement-Eligible AI Solutions

16. BY REGION

16.1. Introduction

- 16.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 16.1.2. Market Attractiveness Index, By Region

16.2. North America

- 16.2.1. Introduction
- 16.2.2. Key Region-Specific Dynamics
- 16.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 16.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
- 16.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity Classification
- 16.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
- 16.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 16.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 16.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration
- 16.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
- 16.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 16.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

- 16.2.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status

- 16.2.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 16.2.14.1. US

- 16.2.14.2. Canada

16.3. Europe

- 16.3.1. Introduction
- 16.3.2. Key Region-Specific Dynamics
- 16.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 16.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
- 16.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

Classification

16.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology

16.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

16.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode

16.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow

Integration

16.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology

16.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

16.3.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

16.3.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory &

Validation Status

16.3.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

16.3.14.1. Germany

16.3.14.2. UK

16.3.14.3. France

16.3.14.4. Russia

16.3.14.5. Italy

16.3.14.6. Spain

16.3.14.7. Norway

16.3.14.8. Netherlands

16.3.14.9. Sweden

16.3.14.10. Denmark

16.3.14.11. Belgium

16.3.14.12. Switzerland

16.3.14.13. Austria

16.3.14.14. Poland

16.3.14.15. Finland

16.3.14.16. Rest of Europe

16.4. Latin America

16.4.1. Introduction

16.4.2. Key Region-Specific Dynamics

16.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component

16.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality

16.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

Classification

16.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology

16.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

16.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode

16.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow Integration

16.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology

16.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

16.4.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

16.4.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status

16.4.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

16.4.14.1. Brazil

16.4.14.2. Argentina

16.4.14.3. Mexico

16.4.14.4. Chile

16.4.14.5. Colombia

16.4.14.6. Peru

16.4.14.7. Rest of Latin America

17. ASIA-PACIFIC

17.1. Introduction

17.1.1. Key Region-Specific Dynamics

17.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component

17.1.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality

17.1.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

Classification

17.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology

17.1.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

17.1.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode

17.1.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow

Integration

17.1.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology

17.1.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

17.1.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

17.1.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory & Validation Status

17.1.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

17.1.13.1. China

17.1.13.2. Japan

- 17.1.13.3. India
- 17.1.13.4. South Korea
- 17.1.13.5. Australia
- 17.1.13.6. New Zealand
- 17.1.13.7. Singapore
- 17.1.13.8. Malaysia
- 17.1.13.9. Thailand
- 17.1.13.10. Indonesia
- 17.1.13.11. Vietnam
- 17.1.13.12. Philippines
- 17.1.13.13. Taiwan
- 17.1.13.14. Rest of Asia Pacific

17.2. Middle East and Africa

- 17.2.1. Introduction
- 17.2.2. Key Region-Specific Dynamics
- 17.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 17.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Screening Modality
- 17.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity

Classification

- 17.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Technology
- 17.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 17.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 17.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Workflow

Integration

- 17.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By AI Technology
- 17.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 17.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

- 17.2.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Regulatory &

Validation Status

- 17.2.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 17.2.14.1. Saudi Arabia
 - 17.2.14.2. United Arab Emirates
 - 17.2.14.3. Qatar
 - 17.2.14.4. Kuwait
 - 17.2.14.5. Oman
 - 17.2.14.6. Bahrain
 - 17.2.14.7. South Africa
 - 17.2.14.8. Egypt

- 17.2.14.9. Nigeria
- 17.2.14.10. Morocco
- 17.2.14.11. Rest of Middle East & Africa

18. COMPETITIVE LANDSCAPE ANALYSIS

- 18.1. Competitive Scenario
- 18.2. Market Positioning/Share Analysis
- 18.3. Mergers and Acquisitions Analysis
- 18.4. Partner Identification Analysis
- 18.5. Investment & Funding Landscape
- 18.6. Strategic Alliances & Innovation Pipelines

19. COMPANY PROFILES

- 19.1. Digital Diagnostics Inc.
 - 19.1.1. Company Overview
 - 19.1.2. Product Portfolio
 - 19.1.3. Revenue Analysis
 - 19.1.4. Pricing Analysis
 - 19.1.5. SWOT Analysis
 - 19.1.6. Recent Developments
 - 19.1.6.1. Major Deals
 - 19.1.6.2. M&A
 - 19.1.6.3. Collaboration
 - 19.1.6.4. Acquisition
 - 19.1.6.5. Joint Ventures
 - 19.1.6.6. Innovations
 - 19.1.7. Recent News
 - 19.1.7.1. Events
 - 19.1.7.2. Conferences
 - 19.1.7.3. Symposiums
 - 19.1.7.4. Webinars
- 19.2. Topcon Healthcare
- 19.3. Eyenuk, Inc.
- 19.4. AEYE Health
- 19.5. IRIS (Intelligent Retinal Imaging Systems).
- 19.6. Optomed Plc
- 19.7. Forus Health (3nethra)

19.8. iCare (LIST NOT EXHAUSTIVE)

20. GLOBAL AI-DRIVEN DIABETIC RETINOPATHY SCREENING MARKET- RESEARCH METHODOLOGY

20.1. Research Data

20.1.1. Secondary Data

20.1.2. Primary Data

20.1.3. CAGR Analysis

20.2. Market Size Estimation Methodology

20.2.1. Bottom-Up Approach

20.2.2. Top-Down Approach

20.3. Market Breakdown & Data Triangulation

20.4. Research Assumptions

20.5. Limitations

21. APPENDIX

21.1. About Us and Services

21.2. Contact Us

I would like to order

Product name: AI-Driven Diabetic Retinopathy Screening Market - 2024-2033

Product link: <https://marketpublishers.com/r/A0D4A8876672EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0D4A8876672EN.html>